Starling Oncology
STLN
119 hedge funds and large institutions have $218M invested in Starling Oncology in 2026 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 51 increasing their positions, 25 reducing their positions, and 21 closing their positions.
1,010% more call options, than puts
Call options by funds: $17.4M | Put options by funds: $1.56M
104% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 25
83% more capital invested
Capital invested by funds: $119M → $218M (+$98.7M)
24% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 21
3% more funds holding
Funds holding: 115 → 119 (+4)
0.88% more ownership
Funds ownership: 39.22% → 40.1% (+0.88%)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
+$5.52M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$3.7M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.38M |
| 4 |
Renaissance Technologies
New York
|
+$1.95M |
| 5 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
+$1.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KWM
Kanen Wealth Management
Coconut Creek,
Florida
|
-$8.53M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$5.61M |
| 3 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$1.92M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.77M |
| 5 |
CP
CenterBook Partners
Greenwich,
Connecticut
|
-$1.37M |
STLN Hedge Fund Activity: Q2 2026 in Review
119 of the 8,339 institutional investors tracked by Wall St. Rank reported a position in Starling Oncology (STLN) for Q2 2026, worth a combined $218M — up 83% from $119M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new STLN positions and 21 closed out — a net gain of 5 holders — while 51 added to existing stakes and 25 trimmed.
The largest buyer was Nuveen, adding an estimated $5.52M. The largest seller was Kanen Wealth Management, exiting entirely with an estimated $8.53M sold.
- 119 institutional investors held Starling Oncology (STLN) as of Q2 2026, up from 115 in Q1 2026.
- Funds reported $218M of Starling Oncology stock for Q2 2026, up 83% quarter-over-quarter.
- 26 funds opened new Starling Oncology positions in Q2 2026 and 21 closed out, a net change of +5 holders.
- The largest Starling Oncology buyer in Q2 2026 was Nuveen, an estimated $5.52M added.
- The largest Starling Oncology seller in Q2 2026 was Kanen Wealth Management, an estimated $8.53M sold.
Based on aggregated 13F filings for Q2 2026.